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Abstract
Focal adhesion kinase (FAK) is a ubiquitously expressed cytoplasmic tyrosine kinase strongly
activated by integrins and neurohumoral factors. Previous studies have shown that cardiac FAK
activity is enhanced by hypertrophic stimuli before the onset of overt hypertrophy. Herein, we report
that conditional deletion of FAK from the myocardium of adult mice did not affect basal cardiac
performance, myocyte viability, or myofibrillar architecture. However, deletion of FAK abolished
the increase in left ventricular posterior wall thickness, myocyte cross-sectional area, and
hypertrophy-associated atrial natriuretic factor induction following pressure overload. Myocyte-
restricted deletion of FAK attenuated the initial wave of extracellular signal-regulated kinase
activation and cFos expression induced by adrenergic agonists and biomechanical stress. In addition,
we found that persistent challenge of mice with myocyte-restricted FAK inactivation leads to
enhanced cardiac fibrosis and cardiac dysfunction in comparison to challenged genetic controls.
These studies show that loss of FAK impairs normal compensatory hypertrophic remodeling without
a concomitant increase in apoptosis in response to cardiac pressure overload and highlight the
possibility that FAK activation may be a common requirement for the initiation of this compensatory
response.
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In the face of chronic pressure or volume overload, the adult heart undergoes pathological
hypertrophic growth. This response is characterized by an increase in cardiomyocyte size and
myofibrillar content as well as an altered pattern of cardiac gene expression, including
induction of immediate early genes and reexpression of several fetal gene transcripts. Initially
these changes are compensatory, but may eventually lead to decreases in cardiac performance
and heart failure.1 The precise molecular mechanisms that regulate anabolic or pathological
myocardial hypertrophy are not completely known, but studies have implicated a variety of
neuroendocrine and autocrine factors, many of which act through G protein-coupled receptors
(in particular those coupled to Gαq).2
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Extensive evidence indicates that extracellular matrix (ECM)/integrin receptor signaling is also
an important regulator of myocardial hypertrophy. Upregulation of collagen III, fibronectin,
osteopontin, or their cognate integrin receptors, β1, α3, and α5, correlates with the advancement
of cardiac hypertrophy in animal models.3 Also transgenic mice that express a myocyte-
restricted activated α5 integrin develop profound cardiac hypertrophy,4 whereas myocyte-
restricted deletion of the β1 integrin in adult mouse hearts leads to a dilated cardiomyopathy
and concomitant heart failure.5,6 In addition, mutations in the structural focal adhesion proteins
muscle LIM protein and metavinculin are associated with dilated cardiomyopathy in patients.
7,8 Collectively, these studies underscore the possibility that defects in integrin signaling may
play a direct role in regulating cardiomyocyte sarcomere formation and function during cardiac
development and disease.
One of the major proteins involved in the integrin intracellular signaling cascade is the
nonreceptor protein tyrosine kinase, focal adhesion kinase (FAK), which is strongly and rapidly
activated by various growth factors and by ligation of all β1-, β3-, or β5-containing integrins.
9 Through multiple protein-protein interactions, activation of FAK results in the subsequent
activation of the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase
(JNK) growth promoting mitogen-activated protein (MAP) kinases and the cytoskeletal
regulating small molecular weight GTPases Rac and Rho, some of the same molecules
implicated in myocyte hypertrophy.2,9
Although a direct role for FAK in cardiac growth and development has yet to be examined,
germline deletion of FAK results in general mesodermal defects and embryonic lethality
between embryonic day 7.5 (E7.5) to E10 (similar to both fibronectin-/- and α5-/- mice) and
fak-/- hearts lack separate mesocardial and endocardial layers, indicative of a defect in
cardiomyocyte maturation.10-12 Interestingly, recent work by our group and by others clearly
indicates that FAK is activated in cultured cardiomyocytes by a variety of hypertrophic
stimuli13-16 and that increased cardiac FAK activity is induced following pressure overload
in vivo.17-20 The idea that FAK activation may play a direct role in the development of
cardiomyocyte hypertrophy is evident from our initial findings that the activation of FAK is
required for phenylephrine (PE)-stimulated hypertrophy of cultured cells and similar findings
from others that FAK is required for maximal endothelin-1 and stretch-induced hypertrophy
in vitro.14,21,22
To test the possibility that FAK inactivation could prevent cardiac hypertrophy in vivo, we
generated a mouse model that produces a conditional myocyte-specific deletion of FAK in the
adult heart. In support of recent findings from Peng et al, we show that inactivation of FAK in
the adult myocardium does not affect basal cardiac function.23 However, we show that hearts
with myocyte-specific FAK depletion do not develop concentric hypertrophy on induction of
biomechanical stress by transverse aortic constriction (TAC). These studies show that FAK
plays a significant role in the development of compensatory hypertrophy in the intact
myocardium and highlight the possibility that FAK serves to integrate growth signals from
various hypertrophic stimuli.
Materials and Methods
Generation of MFKO Mice
Drs Louis Reichardt and Hilary Beggs (University of California, San Francisco) graciously
provided the fakflox mice, and Dr Kenneth Chien (Harvard Medical School) graciously
provided the mlc2vCre knock-in mice.24,25 All mice were backcrossed to the C57black6
background at least 8 generations before subsequent breeding. DNA isolated from tail snips
or tissues was subjected to PCR analysis using primers specific for Cre and the presence of the
targeted or recombined FAK allele as described previously.24,25 Mice were housed in a
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University Animal Care Facility accredited by the American Association for Accreditation of
Laboratory Animal Care.
Statistics
Data are presented as mean±SEM. Means were compared by 2-tailed Student t test. P<0.05
was considered statistically significant.
See the online data supplement, available at http://circres.ahajournals.org, for complete details
of the experimental procedures used herein.
Results
Myocyte-Restricted Deletion of FAK in Adult Mice
We used Cre/loxP technology to test the possibility that FAK inactivation could prevent cardiac
hypertrophy in the intact myocardium. To inactivate the fak gene in a myocyte-restricted
fashion in mice, we bred fakflox mice to those that express Cre recombinase under the control
of the ventricle specific mlc2v promoter (mlc2vCre/wt)25 to obtain fakflox/flox/mlc2vCre/wt mice,
hereafter, referred to as myocyte specific fak knockout mice (MFKO) (Figure 1A).
MFKO mice were born with the expected Mendelian frequency (Figure 1A), and we observed
the selective appearance of the excised, recombined fak gene in the MFKO ventricles at 4
weeks postnatal (not shown), with maximal recombination occurring by 3 months (Figure 1B).
Western analysis confirmed that FAK protein was dramatically reduced in MFKO ventricular
lysate by 3 months postnatal, whereas FAK protein levels remained constant in other tissues
including skeletal muscle, stomach, and brain (Figure 1C and 1D). The low level of FAK
protein remaining in the ventricular lysates from 3 months onward was likely attributable to
its continuing expression in resident nonmyocyte cells (ie, cardiac fibroblasts, smooth muscle,
and endothelial cells) that do not express Mlc2v.
FAK Is Not Required for Basal Cardiac Function
Disruption of FAK expression in the adult heart did not lead to any overt abnormalities. Both
sexes of MFKO mice lived a normal lifespan, were fertile, and females did not exhibit any
complications during pregnancy, indicating that FAK is not required for the maintenance of
normal heart function. In confirmation of this, we found no evidence of left ventricular (LV)
dysfunction as assessed by fractional shortening (FS) and ejection fraction (EF) derived from
M-mode echocardiographs of the left ventricle of young (4-month) or old (14-month) hearts
from MFKO mice in comparison with aged matched genetic controls (Figure 2A and the Table).
At 14 months of age, both lines of mice had a significant reduction in FS and MFKO mice had
a significant reduction in EF when compared with the 4-month-old controls, but no significant
differences in these parameters were observed between age-matched controls (Figure 2A and
the Table). Importantly, no significant difference was observed in posterior (PW) or
intraventricular septal (IVS) wall thickness or LV chamber size, between the 4-month-old
MFKO and genetic controls (fakflox/floxmlc2vwt [Table] or fakwt/wtmlc2vCre [data not shown]).
Hemodynamic analysis by cardiac catheterization also revealed no significant differences in
intrinsic contractility, diastolic function, and cardiac output between control and MFKO mice
at 4 months of age, consistent with a previous report23 (and data not shown). In addition, 4-
to 5-month-old MFKO mice had similar LV weight (LVW):body weight (BW) ratios (Figure
3C), cardiomyocyte cross-sectional area, myofibrillar organization, and levels of fibrosis
compared with littermate controls (Figures 2C and 2D and 3C), indicating that the young
MFKO mice are phenotypically indistinguishable from genetic controls.
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Myocyte-restricted FAK deletion did have a slight but significant effect on heart growth during
aging. HW/BW was significantly decreased in 14-month MFKO mice relative to aged matched
controls (Figure 2B), and myocyte cross-sectional area was reduced slightly (by 5%; P=0.04;
data not shown). Consistent with these findings, serial echocardiographic measurements
revealed a significant increase in thickness of LV posterior wall from 4 to 14 months in control
mice but not in MFKO mice (Table). Histochemical analysis of hearts from aged MFKO mice
(14 months) revealed an increase in interstitial fibrosis in comparison to age matched controls
(Figure 2C and supplemental Table I), but no noticeable differences were found in sarcomeric
integrity or myocyte alignment in comparison to hearts from age-matched control mice (Figure
2C and 2D). Thus, the absence of FAK in cardiac muscle is functionally tolerated, but FAK
may regulate anabolic myocyte growth.
We next asked whether the depletion of FAK from myocytes was tolerated because of a
compensatory increase in the FAK-related protein PYK2/CADTK, which is known to have
increased expression in fak-/- embryos and cells.26,27 However, we found comparable PYK2
protein levels (and activity) in control and MFKO hearts (Figure 2E; data not shown), indicating
that PYK2 does not compensate for loss of FAK in this model.
Pressure Overload-Induced Structural Remodeling and Hypertrophic Gene Expression Is
Attenuated in MFKO Mice
The absence of underlying developmental defects in the conditional MFKO mice at 4 to 5
months of age renders this model advantageous for determining whether FAK is important for
the progression of pathological cardiac hypertrophy. Four-month-old control and MFKO mice
were therefore subjected to a minimally invasive aortic banding procedure that provided an
approximate 50% reduction in the lumen of the ascending aorta. Blinded echocardiographic
measurements revealed several striking differences between the age-matched genetic controls
and MFKO hearts following 4 weeks of TAC (Figure 3A through 3C and the Table). Notably,
the control TAC mice developed significant thickening of LVPW and IVS (approximately 50%
and 30% increases in systole respectively), a significant reduction in left ventricular end
diameter (LVED) (approximate 40% decrease in end diastolic chamber dimension), and a 40%
increase in FS compared with nonbanded control mice. In contrast, the MFKO mice did not
exhibit significant increases in left ventricular posterior wall thickness systole (LVPWT) or
FS comparison to the prebanded MFKO mice (Table). Indeed, the percent change of each
parameter from pre- to post-TAC was significantly decreased in MFKO hearts in comparison
to control hearts (Figure 3A). Measurements from serial cross-sections though banded control
and MFKO hearts confirmed a significant reduction in relative LVPWT in 15 of 19 of the 4-
week post-TAC MFKO hearts in comparison with the control hearts (Figure 3B; data not
shown). Importantly, morphometric analysis revealed a significant decrease in myocyte cross-
sectional area in the post-TAC MFKO hearts compared with post-TAC controls (Figure 3C).
Although a significant increase in LVW/BW was observed following 4 weeks of TAC in
MFKO hearts (possibly attributable to increased fibrosis; see below), the increase in MFKO
hearts was reduced relative to control hearts (Figure 3C). Notably, no significant difference in
the surgically induced intensity of pressure overload was observed between MFKO and the
genetic controls as assessed by Doppler imaging (supplemental Figure I). A comparable
concentric hypertrophic response was observed in our 2 groups of control mice
(fakflox/floxmlc2vwt [shown] and fakwt/wtmlc2vCre [data not shown]), indicating that the lack
of concentric hypertrophy observed in the MFKO mice was not attributable to adverse effects
of either the LoxP-targeted fak allele, expression of Cre, or haploinsufficiency of Mlc2v.
While this report was under review, a separate article was published in which the authors
suggested that cardiac-restricted inactivation of FAK leads to cardiac dilation because of an
eccentric hypertrophic response.23 Therein, Peng et al examined mice at only 1 time point
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following TAC (10 days), which was not sufficient to induce concentric hypertrophy in their
control animals, but they observed a significant increase LV chamber dimension in their CFKO
mice when compared with banded controls.23 To determine whether the change in chamber
size was a primary or secondary response in our model, we banded a second group of mice
(n=7 control and MFKO) and examined their hypertrophic response by blinded
echocardiography at 10 days and 4 weeks following TAC. As shown in Figure 3D, no
significant differences were observed between either LVPW or LVED between MFKO and
control hearts at 10 days following banding. However, similar to our previous large study of
mice (the Table), this separate study revealed a significant decrease in LVPW in 4-week banded
MFKO hearts in comparison with 4-week banded control hearts. This change in LVPWT was
accompanied by an increase in LVED in MFKO hearts relative to banded genetic controls but,
like in our previous study, MFKO LVED was not significantly increased from baseline MFKO
hearts. Because the echocardiographic measurements for this new data set were taken while
mice were under heavier sedation (see Materials and Methods for details), the data were
analyzed separately and are presented in full in supplemental Table II. These studies confirm
our contention that FAK inactivation inhibits the compensatory concentric hypertrophic
response following TAC.
Enhanced perivascular fibrosis as assessed by Masson’s Trichrome staining was observed
following TAC in both control and MFKO TAC hearts with more interstitial fibrosis found in
MFKO TAC hearts (blue staining, Figure 4A, top; supplemental Table I). However, there was
no significant difference in sarcomeric structure or integrity between control and MFKO hearts
following TAC as visualized by troponin T staining (Figure 4A and 4B). Also, we did not find
any significant difference in the level of apoptosis in control or MFKO hearts at baseline or
following banding (Figure 4B and supplemental Figure II). Although PYK2 expression did
increase following TAC, we found no significant difference in PYK2 levels (or activity) in
MFKO TAC hearts relative to control TAC hearts (Figure 4C; data not shown). Collectively,
these data indicate that FAK is not required for the maintenance of proper myocyte architecture
but is required for the promotion of biomechanical stress-induced myocyte hypertrophy.
Hearts from control and MFKO nonbanded and 4-week TAC-induced mice were also analyzed
for hypertrophic marker gene expression by quantitative RT-PCR. We examined the expression
of atrial natruretic factor (ANF) because increased levels of this gene correlate highly with the
degree of hypertrophy observed in several animal models.28 As shown in Figure 5, ANF
expression was, as expected, dramatically increased in the control mice after TAC. This
increase was virtually abolished in the MFKO hearts (Figure 5A). Interestingly, banded MFKO
hearts displayed a significant increase in α-myosin heavy chain (α-MHC) compared with
banded controls whereas no significant difference in β-MHC or skeletal α-actin was observed
between the 2 groups postbanding (data not shown). Collectively our data indicate that loss of
FAK alters the structural and a subset of the molecular changes induced by pressure overload.
Persistent Pressure Overload in MFKO Mice Leads to Cardiac Dysfunction
Because the MFKO TAC hearts exhibited a reduced compensatory response following 4 weeks
of pressure overload, we asked whether the MFKO mice would progress to heart failure after
a more persistent challenge. Although greater than 90% survival was observed in control and
MFKO mice banded for 8 to 12 weeks, the wet lung weights from the MFKO 8-week TAC
group were significantly higher than nonbanded mice, indicating substantial congestion and
the likelihood that the MFKO hearts were failing (Figure 6A). Accordingly, significant
depression of cardiac output, a measure of contractile performance, was apparent in MFKO
mice 12 weeks after TAC (Figure 6B). The decreased contractility in the MFKO mice was
associated with an increase in interstitial fibrosis relative to control-banded hearts at 8 and 12
weeks (supplemental Table I). However, sarcomeric integrity was maintained in these hearts
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as assessed by troponin T staining (data not shown). These data indicate that the MFKO mice
develop heart failure in response to chronic pressure overload and suggest the possibility that
the blunted compensatory hypertrophic response in these mice was not sufficient to meet the
increased hemodynamic demand.
Absence of FAK Impairs MAP Kinase Activation Following Hypertrophic Stimuli
It is possible that the requirement for functional signaling through FAK in pressure overload-
induced hypertrophy may be attributable to the ability of FAK to coactivate an essential growth
pathway. Because ERK activation by hypertrophic stimuli precedes the characteristic changes
in gene expression and inhibition of this signaling pathway can lessen maladaptive
hypertrophic growth,29,30 we evaluated ERK activity in control and MFKO hearts subjected
to aortic banding for 1 and 4 days. Immunoblot analysis revealed reduced levels of ERK
phosphorylation in MFKO hearts in comparison with control hearts after acute aortic
constriction, although no change was observed at baseline (Figure 7A). Because cardiac
hypertrophy induced by pressure overload and neurohumoral signals share some common
mechanisms, we also examined ERK activation induced by adrenergic agonists in control and
MFKO hearts. We injected an adrenergic cocktail previously shown to induce a strong
hypertrophic response in mice.31 As shown in Figure 7B, ERK was strongly activated in
control hearts following acute adrenergic agonist injection but was significantly lower in the
MFKO hearts. We also examined activation of the immediate early gene cFos following acute
banding. We found that cFos expression was significantly upregulated in control hearts 4 days
after TAC but returned to baseline by the 7-day time point (Figure 7C). However, no significant
increase in cFos expression was observed in MFKO hearts following banding, in accordance
with data indicating that activation of cFos is dependent on ERK signaling (Figure 7C). These
data indicate that ERK activation is uncoupled in the absence of FAK and highlight the
possibility that FAK activity is required for the initial wave of signaling induced by both
pressure overload and adrenergic stress.
Discussion
Previous work by our group and others indicate that FAK is important in the hypertrophic
response. Herein, we have used a mouse model in which myocyte-restricted FAK deletion in
early adulthood results in mice whose hearts are functionally and morphologically similar those
of control mice, confirming recent work from Peng et al.23 However, we found that myocyte-
restricted deletion of FAK depressed heart growth during aging and markedly reduced the
hypertrophic response to transverse aortic constriction as assessed by examination of several
conserved features of pathological hypertrophy. Our data indicate that inhibition of FAK
signaling alone is sufficient to suppress the diverse signaling inputs within the complex
myocyte microenvironment in vivo that can modulate cardiac growth induced by stress and
aging.
Our findings that FAK inactivation attenuates concentric hypertrophic remodeling differ with
the conclusions drawn in the aforementioned manuscript by Peng et al, who observed chamber
dilation (or eccentric growth) in FAK-null hearts following 10 days of TAC.23 This
discrepancy could be attributable to differences in the timing of FAK deletion, the extent of
aortic constriction imposed in the 2 models, and/or the genetic background of the mice used
in these studies. (See the online data supplement for further details.) The late onset of
recombination in our model system (3 months postnatal) was somewhat surprising because the
mlc2v promoter has been reported to drive Cre expression as early as E8.5; however, our results
are consistent with several studies showing that maximal recombination of targeted genes is
not observed until at least 6 weeks after birth (and some even later) using the same line.5,32
A distinct advantage of using our MFKO line is that it enables examination of a direct role for
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FAK in the progression of adult onset cardiac diseases in mice that do not have any underlying
developmental defects.
It is interesting that FAK is dispensable for basal myocyte function, whereas depletion of
integrin receptors or various cytoskeletal components including vinculin, muscle LIM protein,
desmin, plakoglobin, or N-cadherin all lead to rapid defects in sarcomeric integrity
accompanied by considerable interstitial fibrosis.3 These data indicate that although FAK co-
resides with these cytoskeletal proteins in Z-disks, it is not an integral component of the
contractile apparatus in myocytes. However, we did find that following persistent challenge
MFKO hearts exhibited systolic dysfunction relative to control-banded hearts. This was likely
a secondary effect attributable to insufficient compensation in response to TAC, because this
model induces a rapid and severe remodeling response in control animals. There is some
evidence indicating that the switch from hypertrophy to cardiac failure may involve activation
of apoptotic pathways. Although we did observe a greater extent of interstitial fibrosis in
banded and aged MFKO hearts (likely because of increased myocyte dropout), we did not
observe an increase in apoptosis or apoptotic markers at the time points examined. These data
corroborate our previous studies showing that FAK inhibition in cultured cardiomyocytes did
not induce programmed cell death and studies from others, indicating that targeted deletion of
FAK in keratinocytes or neurons did not induce apoptosis (see the online data supplement for
further discussion).14,24,33 Taken together, these data indicate that the ensuing dysfunction
in MFKO hearts is likely attributable to a passive necrotic process.
As a multifunctional adapter protein that associates with the integrin cytoplasmic tail, with
actin, and with several adapter proteins that regulate various catalytic signaling molecules,
FAK is an ideal candidate to sense and respond to hormonal imbalances and/or alterations in
the force-generating actin cytoskeleton by inducing coordinate activation of downstream
hypertrophic growth signaling pathways. Our study revealed that myocyte-specific depletion
of FAK dramatically reduces biomechanical stress or hypertrophic agonist-stimulated ERK
activation. Given that activation of the MEK1-ERK1/2 signaling pathway in vivo precedes the
induction of hypertrophic gene expression and that inhibition of these signaling pathways can
lessen hypertrophic growth, it is reasonable to assume that reduced ERK activation may be the
primary mechanism responsible for the blunted hypertrophic response in MFKO hearts.2,29,
30
In conclusion, our analysis of MFKO mice reveals that FAK is essential for the heart to sense
and transduce a biomechanical insult into a compensatory hypertrophic response. This effect
is likely attributable to the ability of FAK to modify the initial wave of ERK-dependent
signaling induced by hypertrophic stimuli. Because cardiac hypertrophy induced by pressure
overload and neurohumoral signals share common mechanisms, and because signaling from
adrenergic receptors is depressed in MFKO hearts, it is possible that activation of FAK may
be a common requirement for the initiation of the pathological hypertrophic response.
Interestingly, recent studies have shown that whereas disruption of MEKK1 (like FAK)
eventually leads to cardiac decompensation following pressure overload, inactivation of
MEKK1 actually prevents systolic dysfunction induced by Gαq.34,35 Thus, further studies
coupling various hypertrophic model systems with cardiac-targeted FAK disruption should
lead to important new information with regard to the transition from compensatory to
decompensated stages of cardiac hypertrophy and aid in determining under which
circumstances FAK-dependent signaling pathways may be protective or detrimental. Whether
targeted inhibition of FAK would be beneficial for the treatment of heart disease will likely
depend on the contributing factors for disease.
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Targeted myocyte specific disruption of mouse focal adhesion kinase. a, Diagrammatic
representation of the fakflox/flox and mlc2vCre/wt breeding strategy (n=725). b, PCR analyses
of heart DNA from wild-type mice (wt) (1.4-kb band), Flox (1.6-kb band), and MFKO mice
(recombined allele generates 327-bp band). c, Protein extracts from 3-month-old control (C)
and MFKO ventricles were processed by SDS-PAGE and probed with anti-FAK or anti-ERK
antibodies. Densitometry quantification of FAK expression compared with an ERK loading
control (right, n=3). d, Protein extracts from skeletal muscle, stomach, and brain from 3-month-
old control (C) and MFKO mice processed as described above using an anti-FAK antibody.
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FAK is required for myocyte growth but not for maintenance of myocyte cyto-architecture. a,
Baseline function of 4-month and 14-month-old control (C) and MFKO hearts as determined
by M-mode echocardiography (*P<0.05 when compared with baseline genetic control; see the
Table for measured values and number of mice/condition). b, LV weight to body weight ratio
for 14-month-old control (n=10) and MFKO (n=6) mice. *P<0.05. c, Left ventricles from
indicated ages of control and MFKO mice were processed for histology as described in
Materials and Methods and stained with Masson’s Trichrome to reveal myocyte organization
and level of fibrosis (blue). d, Sections of left ventricle from control and MFKO mice were
stained with an anti-cardiac troponin T antibody to reveal myofibrillar organization. e,
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Immunoblot of protein extracts from 4-month control or MFKO ventricles were probed with
anti-PYK2 (top) or anti-ERK antibodies (bottom). Densitometry quantification of PYK2
expression compared with an ERK loading control (right, n=4).
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FAK is essential for pressure overload-induced hypertrophy. a, M-mode echocardiograph
measurements of the left ventricles from baseline and banded control and MFKO mice during
diastole (d) and systole (s) were analyzed for percent change from pre- to post-TAC. *P<0.05
when compared with percent change in control mice. b, Ventricles from sham and 4-week
banded control and MFKO hearts were stained with Trichrome to reveal gross changes in wall
thickness and chamber dimensions following 4-weeks of TAC. c, LVW to BW ratio (top).
Cross-sectional myocyte area of sham and 4-week banded control and MFKO myocytes
(middle, n=at least 175 per condition). *P<0.05 for indicated comparison. Representative LV
sections stained with lectin reveals reduced cross-sectional area in MFKO myocytes compared
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with controls following 4-weeks of TAC (bottom). d, Comparison of LV posterior wall and
chamber size in both control and MFKO mice. *P=0.01 vs control 4-week banded control.
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Post-TAC MFKO hearts have increased fibrosis but MFKO myocytes display normal
cytoarchitecture. a, Images of Trichrome-stained sections (×10) (top) or images of sections
stained with cardiac troponin T antibody (bottom) (×40) reveal increased fibrosis but normal
cell-cell interactions and myofibrillar organization in control and MFKO hearts. b,
Transmission electron micrographs from the mid-wall region of the left ventricle of 4-week
banded control and MFKO mice taken at ×4000, ×10 000, and ×20 000 magnification. c,
Western blot analysis of PYK2 protein levels following 4-week TAC of control (C) and MFKO
mice. Densitometry quantification of Pyk2 expression compared with an ERK loading control
(right, n=5).
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FAK modulates ANF expression following TAC. Quantitative RT-PCR analysis for ANF (a)
and α-MHC (b) RNA levels from sham and banded control and MFKO hearts. Data were
normalized to β-actin levels and presented as fold over values from sham control mice.
*P=0.03 vs banded control.
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Chronic banding leads to systolic dysfunction in MFKO mice. a, Wet lung and body weight
measurements were taken from control and MFKO sham-treated mice or mice banded for 4 or
8-weeks. *P=0.03 vs experimental control n=4 (or more) for each group. b, Sham or 12-week
banded control and MFKO mice were subjected to cardiac catheterization as described in
Materials and Methods to examine contractile function. *P=0.03 vs 12-week banded control
(n=at least 4 for each group).
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FAK is required for maximal ERK activation induced by banding and adrenergic stress. a,
Western blot analysis of phopspho-ERK1/2 following 1 or 4 days of aortic constriction in
control and MFKO mice. Densitometry quantification of phospho-ERK1/2 compared with an
ERK loading control (right, n=3). b, Control (C) and MFKO mice were injected with a
adrenergic cocktail for 7 minutes containing PE and isoproterenol (30 mg/kg each) or PBS into
the intraperitoneal cavity. Ventricular lysate was processed for Western blot analysis using
anti-FAK, phospho-ERK1/2, and total ERK1/2 (loading control) antibodies. Densitometry
quantification of phospho-ERK1/2 compared with an ERK loading control (right, n=3). c, RNA
was extracted from control and MFKO hearts at days 0, 4, and 7 following banding and
processed for quantitative RT-PCR using the c-fos probe and primers detailed in Materials and
Methods. *P=0.03 vs 4-day banded control mice.
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